NCT02789345 2024-02-05
A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer
Eli Lilly and Company
Phase 1 Completed
Eli Lilly and Company
Glycotope GmbH
Eli Lilly and Company
Eli Lilly and Company